HLIO:NYSEHelios Technologies, Inc. Analysis
Data as of 2026-04-08 - not real-time
$65.72
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Helios Technologies delivered a strong fourth‑quarter, posting $210.7 million in sales and $48.4 million in full‑year net income, while guiding FY 2026 revenue to $820‑$860 million and completing a 330,000‑share buyback. Revenue grew 17.4% YoY and the board announced a 33% increase in the quarterly dividend, underscoring confidence in cash‑flow generation.
On the technical side, the stock trades at $65.72, comfortably above the 20‑day SMA of $65.45 but below the 50‑day SMA of $68.60, with a bullish MACD crossover (histogram +0.25) and rising volume supporting short‑term upside toward the $69.18 resistance. The 30‑day volatility of ~41% and a beta of 1.34 signal heightened price swings, yet the current price sits near a solid $62.05 support level.
Valuation is mixed: a trailing PE of 45.3 versus the industry average of 29.6 suggests the stock is priced high, but the DCF fair value of $68.46 and a forward PE of 20.5 point to a fair valuation with roughly 21% upside to the consensus $79.5 target. Analyst sentiment is strongly positive ("strong_buy"), and the dividend yield of 0.73% with a 24.8% payout ratio appears sustainable given robust operating cash flow.
On the technical side, the stock trades at $65.72, comfortably above the 20‑day SMA of $65.45 but below the 50‑day SMA of $68.60, with a bullish MACD crossover (histogram +0.25) and rising volume supporting short‑term upside toward the $69.18 resistance. The 30‑day volatility of ~41% and a beta of 1.34 signal heightened price swings, yet the current price sits near a solid $62.05 support level.
Valuation is mixed: a trailing PE of 45.3 versus the industry average of 29.6 suggests the stock is priced high, but the DCF fair value of $68.46 and a forward PE of 20.5 point to a fair valuation with roughly 21% upside to the consensus $79.5 target. Analyst sentiment is strongly positive ("strong_buy"), and the dividend yield of 0.73% with a 24.8% payout ratio appears sustainable given robust operating cash flow.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish MACD crossover with positive histogram
- Price above 20‑day SMA and near strong support
- Recent earnings beat and share buyback supporting demand
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Revenue growth of 17% and FY guidance indicating continued expansion
- Analyst consensus target of $79.5 implying ~21% upside
- Dividend increase and sustainable payout ratio
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- CORE 2030 strategic roadmap targeting higher‑margin solutions
- Consistent free cash flow and manageable debt levels
- Blend of growth prospects and dividend income for total return
Key Metrics & Analysis
Financial Health
Revenue Growth17.40%
Profit Margin5.77%
P/E Ratio45.3
ROE5.39%
ROA3.86%
Debt/Equity41.46
P/B Ratio2.3
Op. Cash Flow$127.3M
Free Cash Flow$93.5M
Industry P/E29.6
Technical Analysis
TrendNeutral
RSI47.9
Support$62.05
Resistance$69.18
MA 20$65.45
MA 50$68.60
MA 200$55.09
MACDBullish
VolumeIncreasing
Fear & Greed Index84.86
Valuation
Fair Value$68.46
Target Price$79.50
Upside/Downside20.97%
GradeFair
TypeBlend
Dividend Yield0.73%
Risk Assessment
Beta1.34
Volatility40.91%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.